Durgical
EN
Open the app

Marrow failure: aplastic anaemia, PNH, hypoplastic MDS and inherited syndromes

  • Look-alikes compared

When all counts fall and the marrow is empty, the cause decides everything: immune attack, a faulty clone or an inherited defect, each treated differently.

Updated

What it is

Bone marrow failure is too little production of blood cells by an empty or failing marrow. Acquired aplastic anaemia is an immune attack on the stem cells. Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired stem cell clone that lacks protection against complement and often grows inside aplastic marrow. Hypoplastic myelodysplasia is a malignant clone with an empty marrow. Inherited syndromes (Fanconi anaemia, Diamond–Blackfan anaemia, dyskeratosis congenita) come from faults in DNA repair, ribosomes or telomeres and often carry physical clues and a cancer risk.

The difference in one line

  • Aplastic anaemia: pancytopenia, low reticulocytes, an empty fatty marrow with no abnormal or malignant cells and no fibrosis; a big spleen argues against it.
  • Causes of acquired aplasia: mostly idiopathic immune; also drugs, benzene, radiation, viral hepatitis (seronegative) and pregnancy.
  • PNH: an acquired PIGA mutation removes GPI-anchored proteins (CD55, CD59) so complement lyses red cells; the triad is intravascular haemolysis, thrombosis in unusual veins and marrow failure; diagnosed by flow cytometry.
  • Hypoplastic MDS: an empty marrow with dysplasia, chromosome abnormalities (such as monosomy 7) or excess blasts; more often in older adults.
  • Inherited failure can present in adults; a short stature, skin, nail or thumb anomaly, early grey hair, lung fibrosis or a family history are clues to test for.

Why the field is empty

ConditionWhat failsTypical cluesConfirming testTreatment principle
Acquired aplastic anaemiaT cells destroy stem cellsPancytopenia, empty marrow, no splenomegalyMarrow biopsy (hypocellular, no dysplasia); exclude the othersStem cell transplant if young with a matched sibling; otherwise immunosuppression plus a thrombopoietin agonist
Paroxysmal nocturnal haemoglobinuriaClone lacking complement shields (CD55, CD59)Dark morning urine, haemolysis, unusual thromboses (hepatic, abdominal, cerebral veins)Flow cytometry for GPI-anchored proteinsComplement inhibitors; meningococcal vaccine first
Hypoplastic myelodysplasiaMalignant clone, ineffective productionOlder age, macrocytosis, dysplastic cellsMarrow morphology, cytogenetics, mutation panelMDS-directed treatment; transplant in selected patients
Fanconi anaemiaDNA cross-link repairShort stature, thumb or radius anomalies, café-au-lait spots; childhood onsetChromosome breakage testTransplant with gentle conditioning; cancer surveillance
Diamond–Blackfan anaemiaRibosome production in red cell precursorsRed cells only, in infancy; macrocytosis; thumb or facial anomaliesLow reticulocytes, raised red cell adenosine deaminase, ribosomal gene testingGlucocorticoids, transfusion, transplant
Dyskeratosis congenitaTelomere maintenanceNail dystrophy, lacy skin pigmentation, white mouth patches, lung fibrosisTelomere length testing, genetic panelTransplant with gentle conditioning; surveillance

In clinical practice

  • Pancytopenia with fever is a neutropenic emergency until shown otherwise: cultures and antibiotics come before the marrow biopsy.
  • Small PNH clones are found in many patients with aplastic anaemia; they are monitored because they can grow.
  • Patients who may need a transplant should receive irradiated, leukoreduced blood and avoid unnecessary transfusions from family members, which can sensitise them against a future donor.
  • Fanconi anaemia and dyskeratosis congenita bring a high risk of head and neck squamous cancers and leukaemia; they also make chemotherapy and radiation unusually toxic.
  • An apparently acquired aplastic anaemia in a young adult with early grey hair, lung fibrosis or a family history of liver or lung disease should prompt telomere testing before immunosuppression or transplant.

How it is confirmed

  • Pancytopenia: blood film, reticulocytes, B12 and folate, viral tests (hepatitis, HIV, parvovirus B19), and a marrow aspirate and biopsy with cytogenetics.
  • Every aplastic or unexplained haemolytic picture: PNH flow cytometry on peripheral blood.
  • Children and young adults with marrow failure: chromosome breakage test for Fanconi anaemia and telomere length testing before choosing treatment.
  • Isolated anaemia in an infant with low reticulocytes: red cell adenosine deaminase and ribosomal gene testing for Diamond–Blackfan anaemia.
  • HLA typing of the patient and siblings early, for transplant planning.

Common traps

  • Calling a hypocellular marrow aplastic anaemia without cytogenetics: hypoplastic MDS can look the same and is treated differently.
  • Skipping Fanconi anaemia and telomere testing in a young patient before immunosuppression or a standard transplant: the conditioning can be lethal and a related donor may carry the same defect.
  • Missing PNH in a patient with a hepatic or abdominal vein thrombosis: when there is also unexplained haemolysis, PNH must be considered.
  • Giving complement inhibitors without meningococcal vaccination: blocking complement greatly raises the risk of meningococcal infection.

Test yourself

Think of the answer, then tap the question to see it.

Why does a big spleen argue against acquired aplastic anaemia in a patient with pancytopenia?

Aplastic anaemia empties the marrow without infiltrating organs; a big spleen points to another cause such as lymphoma, leukaemia, myelofibrosis, hypersplenism or infection.

Which test separates hypoplastic MDS from aplastic anaemia, and why does it matter?

Marrow cytogenetics and morphology: chromosome changes or dysplasia mean a malignant clone, which needs MDS-directed treatment rather than immunosuppression alone.

Why must a young patient with marrow failure be tested for Fanconi anaemia before a transplant?

Faulty DNA repair makes standard chemotherapy and radiation conditioning very toxic, and an affected sibling would be an unsuitable donor.

A patient with PNH is starting a complement C5 inhibitor. What must come first, and why?

Meningococcal vaccination (and often antibiotic cover): blocking terminal complement removes the main defence against Neisseria meningitidis.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Aplastic anemia (MedlinePlus, US National Library of Medicine, 2025); Paroxysmal nocturnal hemoglobinuria: MedlinePlus Genetics (MedlinePlus, US National Library of Medicine, 2026); Fanconi anemia: MedlinePlus Genetics (MedlinePlus, US National Library of Medicine, 2026); Diamond-Blackfan anemia: MedlinePlus Genetics (MedlinePlus, US National Library of Medicine, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.